LEP and lipodystrophy: Based on these key findings, metreleptin, the recombinant human leptin analog, has been adopted as the therapeutic of choice for the treatment of lipodystrophy and approved by the US Food and Drug Administration (FDA) in February 2014 for the treatment of metabolic abnormalities in patients with congenital generalized and acquired lipodystrophy34.